perspective article (1) . There is only a 5% amino acid sequence difference between the two reported GPI-anchored mesothelin variants (1, 5) , which may have minimal impact for applications such as mesothelin-targeted vaccines or immunotoxin therapies. Likewise, the absence of a "soluble mesothelin" variant does not rule out the possible utility of circulating mesothelin as a diagnostic or prognostic marker. Mesothelin is a GPI-anchored membrane protein, and there are several described pathways for the release of GPI-proteins from the cell surface (7) . Carcinoembryonic antigen (CEA) is a prime example of a GPI-anchored protein overexpressed by many carcinomas and efficiently released into the circulation, so that serum CEA levels are used clinically as surrogate markers of disease progression in patients with CEA-expressing tumors. In this context, the precise mechanisms of mesothelin release into the circulation may be relatively unimportant for most proposed applications. However, studies based on mesothelin mRNA expression may be adversely affected by incorrect assumptions of the target mesothelin transcript sequence. In Response: Dr. Shaw and colleagues have emphasized that there is confusion in the literature about the nomenclature used to describe the mesothelin gene, RNA transcripts, and the proteins encoded by these transcripts. This confusion is one of the reasons that we felt it was important to write a review on the subject of mesothelin (1). Our group identified mesothelin by expression cloning using monoclonal antibody K1 and a cDNA library prepared from HeLa cells (2) . The cDNA sequence of mesothelin is very similar to the that of cDNA encoding the megakaryocyte potentiating factor described by Kojima et al. (3) . Since that time, 150 sequences related to mesothelin have been deposited in various databases. Based on an analysis of these data, we concluded that the major mesothelin transcript encodes a protein of 622 amino acids. This is exactly the major transcript described in the paper by Muminova, Strong, and Shaw published after submission of our review (4). So we are in total agreement on this point. We chose to call the major transcript mesothelin, whereas they labeled it variant 1. We hope that this discrepancy will not cause further confusion. We chose not to call the major transcript a variant because it was so abundant and reserved the use of variant for minor transcripts.
Mesothelin V-1 is the sequence originally reported by our group in 1995 (GenBank accession no.U40434) and has a sequencing error in the region of codon 4-56, as mentioned by Shaw and colleagues. The difference between mesothelin and V-1 is an eight-amino-acid insertion (APRRPLPQ) as shown in Fig. 1 of ref. 4. This insertion is also reported in another expressed sequence tag in the database (GenBank accession no. CB266931), which suggests that this could be a minor but real splice variant of mesothelin. Mesothelin V-2 is supported by the existence of four expressed sequence tags (GenBank accession nos. AA404695, AI469957, AA291488, and AA291639) in the database and was also reported by Scholler et al. as a minor splice variant of mesothelin (5) .
The total sequence of the protein in the circulation that is reported by Scholler et al. (5) and that is described as the secretory form of mesothelin is unclear. They report that its NH 2 -terminal amino acid sequence, EVEKTACPSGKKA-REIDES, is identical to mesothelin (in the region of codons 296 -314), but their report did not describe its COOH-terminal sequence. We noted in our review that mesothelin V-2 could be a result of abnormal splicing. However, as pointed out by Dr. Shaw, soluble mesothelin could also represent mesothelin that is shed from the cell surface. Isolation and sequencing of the soluble form of mesothelin in serum will determine whether the secretory form of mesothelin is encoded by variant 2 or whether it represents mesothelin that is shed from the cell surface.
In conclusion, we agree with Dr. Shaw that the major transcript of the mesothelin gene in human cells and tissues is the upper mesothelin protein that was diagrammed in Fig.  2B in our review and that was referred to simply as mesothelin (1). We are also in agreement that the mesothelin sequence in the GenBank accession no. NM_005823 should be considered as the default sequence for investigations targeting mesothelin (3).
Vascular Endothelial Growth Factor in Predicting Outcome in Breast Cancer
To the editor: We have read with great interest the work by Konecny et al. about HER-2/neu and vascular endothelial growth factor (VEGF) expression and breast cancer outcome (1). As we reported recently, a polymorphism downstream of the VEGF gene, 936CϾT, was associated with VEGF expression and breast cancer risk (2) . Encouraged by the data of Konecny et al., we have retrieved data on metastasis in the 500 breast cancer patients from our study and performed a retrospective analysis of metastasis-free survival time. A Cox regression model, including VEGF 936T carriage, age at diagnosis, primary presence of regional lymph node metastasis, primary tumor size larger than 2 cm, and estrogen and/or progesterone receptor negativity in the primary tumor, was used to estimate the effect of the VEGF genotype on metastasis-free survival time. The study was performed according to the Austrian Gene Technology Act and has been approved by the Ethical Committee of the Medical University Graz. Written informed consent was obtained from all participating subjects. All subjects were Caucasian.
At the time of diagnoses, patients were between 28 and 84 years of age, with a mean age of 57 Ϯ 11 years. Median time to metastasis was 34 months. Genotype frequencies were 82.4% (CC), 15.8% (CT) and 1.8% (TT). In a subgroup of 210 patients with low-grade breast cancer (histologic grade 1 or 2), 77 patients developed metastases in the time between diagnosis and study entry. The VEGF 936-T allele was protective against metastasis (Fig. 1) , showing a relative risk of
